Subsequently, CD8 + T-cells, orchestrated by the presence of the peptide antigen, generate specific cytotoxic lymphocytes that identify and dismantle tumor cells expressing the antigen.[8] In contrast to other peptide vaccines, such as E75, which functions by instigating CD8 + T-cells to obliterate tumor cells directly, AE37 adopts a revolutionary approach. Here, CD8A is linked to neoplasm.